Q-omics provides the consensus-scored ANKRD30A profile across patient tissues and cancer cell-line models. ANKRD30A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANKRD30A is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, ANKRD30A RNA expression shows 10,161 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, and BRCA as cancer lineages where ANKRD30A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD30A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD30A survival associations across molecular data types. ANKRD30A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD30A RNA expression–survival associations across cancer types. High ANKRD30A expression shows unfavorable associations in KIRC, HNSC, SCLC, BLCA and UCS, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANKRD30A RNA expression.
This table summarizes ANKRD30A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD30A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD30A shows lower tumor expression in KIRC and THCA and higher tumor expression in KICH, COAD, LIHC and HNSC. The KIRC box plot shows higher ANKRD30A RNA expression in normal versus tumor tissue (log2 FC = −0.082, t-test p < 0.001).
This table shows molecular features associated with ANKRD30A in patient tissues and cancer cell lines. In patient samples, ANKRD30A shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD30A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
